Published in Nat Rev Drug Discov on October 07, 2014
Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems. Chem Soc Rev (2016) 1.08
Design considerations for nanotherapeutics in oncology. Nanomedicine (2015) 0.96
Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol (2015) 0.91
Biomimetic proteolipid vesicles for targeting inflamed tissues. Nat Mater (2016) 0.90
Stimuli-responsive clustered nanoparticles for improved tumor penetration and therapeutic efficacy. Proc Natl Acad Sci U S A (2016) 0.87
Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. Proc Natl Acad Sci U S A (2015) 0.87
The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (Lond) (2015) 0.86
A comprehensive study of interactions between lectins and glycoproteins for the development of effective theranostic nanoagents. Dokl Biochem Biophys (2015) 0.84
A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. J Control Release (2015) 0.83
Cancer targeted therapeutics: From molecules to drug delivery vehicles. J Control Release (2015) 0.82
Neutrophil-Mediated Delivery of Therapeutic Nanoparticles across Blood Vessel Barrier for Treatment of Inflammation and Infection. ACS Nano (2015) 0.81
Augmenting drug-carrier compatibility improves tumour nanotherapy efficacy. Nat Commun (2016) 0.81
Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform. Lab Chip (2016) 0.81
Mixed Nanosized Polymeric Micelles as Promoter of Doxorubicin and miRNA-34a Co-Delivery Triggered by Dual Stimuli in Tumor Tissue. Small (2016) 0.81
Synthesis of linear and cyclic peptide-PEG-lipids for stabilization and targeting of cationic liposome-DNA complexes. Bioorg Med Chem Lett (2016) 0.79
Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review. Biomed Res Int (2015) 0.79
The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. Oncogene (2015) 0.79
Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. Adv Healthc Mater (2016) 0.78
Elucidation of Exosome Migration across the Blood-Brain Barrier Model In Vitro. Cell Mol Bioeng (2016) 0.78
Reactive oxygen species-activated nanomaterials as theranostic agents. Nanomedicine (Lond) (2015) 0.78
pH-Sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.78
Extracellular control of intracellular drug release for enhanced safety of anti-cancer chemotherapy. Sci Rep (2016) 0.78
Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles. J Nanobiotechnology (2016) 0.78
Inorganic Nanocarriers Overcoming Multidrug Resistance for Cancer Theranostics. Adv Sci (Weinh) (2016) 0.77
Theranostic barcoded nanoparticles for personalized cancer medicine. Nat Commun (2016) 0.77
"Eat me" imaging and therapy. Adv Drug Deliv Rev (2016) 0.77
Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis. Int J Nanomedicine (2016) 0.77
3D Imaging of Nanoparticle Distribution in Biological Tissue by Laser-Induced Breakdown Spectroscopy. Sci Rep (2016) 0.77
Therapeutic Applications of Curcumin Nanoformulations. AAPS J (2015) 0.77
Novel multifunctional pH-sensitive nanoparticles loaded into microbubbles as drug delivery vehicles for enhanced tumor targeting. Sci Rep (2016) 0.77
The Smart Drug Delivery System and Its Clinical Potential. Theranostics (2016) 0.76
A pH-Responsive Host-guest Nanosystem Loading Succinobucol Suppresses Lung Metastasis of Breast Cancer. Theranostics (2016) 0.76
Peptide-drug conjugates as effective prodrug strategies for targeted delivery. Adv Drug Deliv Rev (2016) 0.76
Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. J Control Release (2015) 0.76
siRNA Delivery by Stimuli-Sensitive Nanocarriers. Curr Pharm Des (2015) 0.76
An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. Oncotarget (2015) 0.76
Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma. Biomaterials (2016) 0.76
Photosensitization Priming of Tumor Microenvironments Improves Delivery of Nanotherapeutics via Neutrophil Infiltration. Adv Mater (2017) 0.76
High yield, scalable and remotely drug-loaded neutrophil-derived extracellular vesicles (EVs) for anti-inflammation therapy. Biomaterials (2017) 0.76
Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics (2017) 0.75
Nanomedicines for renal disease: current status and future applications. Nat Rev Nephrol (2016) 0.75
Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer. Nanomaterials (Basel) (2016) 0.75
PET imaging of (64)Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs. Nucl Med Biol (2017) 0.75
Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells. J Mater Chem B Mater Biol Med (2015) 0.75
Tetraphenylethene-based highly emissive metallacage as a component of theranostic supramolecular nanoparticles. Proc Natl Acad Sci U S A (2016) 0.75
Dual-functional lipid-like nanoparticles for delivery of mRNA and MRI contrast agents. Nanoscale (2017) 0.75
Plasmonic/Magnetic Multifunctional nanoplatform for Cancer Theranostics. Sci Rep (2016) 0.75
Role of Aromatic Interactions in Temperature-Sensitive Amphiphilic Supramolecular Assemblies. Langmuir (2016) 0.75
Strategies for using nanoprobes to perceive and treat cancer activity: a review. J Biol Eng (2017) 0.75
Particle-based technologies for osteoarthritis detection and therapy. Drug Deliv Transl Res (2016) 0.75
Chemistry-based molecular signature underlying the atypia of clozapine. Transl Psychiatry (2017) 0.75
Manipulation and Immobilization of a Single Fluorescence Nanosensor for Selective Injection into Cells. Sensors (Basel) (2016) 0.75
Serum protein adsorption and excretion pathways of metal nanoparticles. Nanomedicine (Lond) (2015) 0.75
Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody. Int J Nanomedicine (2016) 0.75
Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy. Expert Opin Drug Deliv (2016) 0.75
Stimuli responsive charge-switchable lipids: Capture and release of nucleic acids. Chem Phys Lipids (2016) 0.75
Silicon Dioxide Impedes Antiviral Response and Causes Genotoxic Insult During Calicivirus Replication. J Nanosci Nanotechnol (2016) 0.75
Stem Cell Extracellular Vesicles: Extended Messages of Regeneration. Annu Rev Pharmacol Toxicol (2016) 0.75
Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. Front Immunol (2017) 0.75
Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat (2015) 0.75
Nanoparticle-based drug delivery systems: What can they really do in vivo? F1000Res (2017) 0.75
Cancer cell death induced by nanomagnetolectin. Eur J Cell Biol (2017) 0.75
Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance. Med Res Rev (2016) 0.75
Tumor microenvironment dual-responsive core-shell nanoparticles with hyaluronic acid-shield for efficient co-delivery of doxorubicin and plasmid DNA. Int J Nanomedicine (2017) 0.75
Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy. Adv Mater (2017) 0.75
Nanoparticles for the treatment of liver fibrosis. Int J Nanomedicine (2017) 0.75
Ligand-decorated click polypeptide derived nanoparticles for targeted drug delivery applications. Nanomedicine (2017) 0.75
Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release. ACS Nano (2017) 0.75
Cell membrane-derived nanoparticles: emerging clinical opportunities for targeted drug delivery. Nanomedicine (Lond) (2017) 0.75
(111)In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues. Biomacromolecules (2016) 0.75
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26
Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol (2007) 6.85
Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci U S A (2007) 5.17
Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett (1990) 5.14
In vivo imaging of siRNA delivery and silencing in tumors. Nat Med (2007) 4.94
Towards more effective advanced drug delivery systems. Int J Pharm (2013) 4.81
Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res (2006) 4.43
High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem (1999) 4.41
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine (2006) 4.08
Molecular imaging in drug development. Nat Rev Drug Discov (2008) 4.06
Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas. Cancer Res (2009) 3.77
PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release (2006) 3.74
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J (2010) 3.68
Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng (1999) 3.64
Stimuli-responsive nanocarriers for drug delivery. Nat Mater (2013) 3.52
Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release (2012) 3.41
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A (2001) 3.06
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release (2010) 3.06
Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res (2007) 3.03
Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev (2008) 2.87
Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem (2010) 2.72
Targeted drug delivery to tumors: myths, reality and possibility. J Control Release (2011) 2.69
Particle size, surface coating, and PEGylation influence the biodistribution of quantum dots in living mice. Small (2009) 2.59
"SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem (2006) 2.58
Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev (2002) 2.56
Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol (2011) 2.45
Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther (2010) 2.30
Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res (2002) 2.29
The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer. Biochim Biophys Acta (1995) 2.10
Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A (2003) 2.05
Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res (1999) 2.00
Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta (1995) 1.92
Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev (2004) 1.90
Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A (2001) 1.89
Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release (2003) 1.89
Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res (2009) 1.86
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano (2012) 1.86
p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim Biophys Acta (2001) 1.82
Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm (2008) 1.78
Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A (2009) 1.76
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res (2011) 1.69
Cancer nanomedicines: so many papers and so few drugs! Adv Drug Deliv Rev (2012) 1.66
Multi-functional polymeric nanoparticles for tumour-targeted drug delivery. Expert Opin Drug Deliv (2006) 1.61
Development of multifunctional nanoparticles for targeted drug delivery and noninvasive imaging of therapeutic effect. Curr Drug Discov Technol (2009) 1.60
Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res (2002) 1.55
Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano (2011) 1.46
Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug Chem (2007) 1.43
Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release (2009) 1.42
Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm (2011) 1.42
Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release (2006) 1.36
Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small (2008) 1.31
Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol (1999) 1.31
Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res (2010) 1.30
Poly(amidoamine) dendrimer-drug conjugates with disulfide linkages for intracellular drug delivery. Biomaterials (2009) 1.29
Mitochondrial gateways to cancer. Mol Aspects Med (2009) 1.28
Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target (2007) 1.27
Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn Reson Med (2007) 1.25
Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release (2011) 1.25
Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release (2009) 1.25
PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. ACS Nano (2008) 1.25
In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm Res (2007) 1.22
Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles. Nanomedicine (Lond) (2008) 1.22
VEGF siRNA delivery system using arginine-grafted bioreducible poly(disulfide amine). Mol Pharm (2009) 1.21
Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release (2008) 1.21
Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study. Mol Pharmacol (2002) 1.20
Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des (2006) 1.20
Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm (2009) 1.18
The use of nitric oxide releasing nanoparticles as a treatment against Acinetobacter baumannii in wound infections. Virulence (2010) 1.18
Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging (2006) 1.17
Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J Control Release (2009) 1.17
Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia (2010) 1.14
Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci (2007) 1.14
P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) (2012) 1.14
Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int J Pharm (2011) 1.13
Controllable inhibition of cellular uptake of oxidized low-density lipoprotein: structure-function relationships for nanoscale amphiphilic polymers. Acta Biomater (2010) 1.13
Photothermally enhanced drug delivery by ultrasmall multifunctional FeCo/graphitic shell nanocrystals. ACS Nano (2011) 1.13
Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev (2001) 1.12
Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol (2005) 1.09
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release (2006) 1.09
Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. Biomaterials (2012) 1.09
In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharm (2009) 1.08
A liposome-based nanostructure for aptamer directed delivery. Chem Commun (Camb) (2009) 1.07
Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res (2009) 1.06
Magnetic iron oxide nanoparticles for multimodal imaging and therapy of cancer. Int J Mol Sci (2013) 1.05
Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem (2009) 1.05
Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release (2001) 1.04
Challenges in development of targeted liposomal therapeutics. AAPS J (2012) 1.03
Near-infrared light-responsive core-shell nanogels for targeted drug delivery. ACS Nano (2011) 1.02
Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo. J Control Release (2010) 1.02
Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol (2009) 1.01
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol (2012) 1.01
Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer (2009) 1.01
Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother (2007) 1.00
Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy. Drug Discov Today (2012) 1.00
Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol (2011) 1.00